// App-Quantinova.ai

TPS6106 : Phase ib trial of dose-escalating AZD1775 in combination with concurrent radiation and cisplatin for intermediate and high risk head and neck squamous cell carcinoma.

Researchers

Presenter

  • Bhishamjit S. Chera

Principal Investigators

  • Gaorav P. Gupta

  • Jared Weiss

  • Juneko E. Grilley-Olson

  • Dominic T. Moore

  • Jose Zevallos

  • Trevor Hackman

  • Samip Patel

  • Adam M Zanation

  • Mark Christian Weissler

  • David N. Hayes

Medical Centers

  • University of North Carolina, Chapel Hill, NC

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC

  • UNC Chapel Hill, Chapel Hill, NC

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC

  • Department of Otolaryngology/Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC

  • Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

Biomarkers

  • p53

  • Histone H2AX

Drug/Treatment

  • Cisplatin

  • AZD-1775

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02585973

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved